Despite its potential, cancer nanomedicine faces several challenges:
Biocompatibility: Ensuring that nanomaterials are non-toxic and do not elicit adverse immune responses. Scalability: Developing cost-effective and scalable production methods for nanomaterials. Regulation: Navigating the complex regulatory landscape to gain approval for clinical use. Targeting Efficiency: Improving the precision of nanoparticle targeting to minimize off-target effects.
